Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma

The emergence of new drugs has provided additional options in the treatment of relapsed and refractory (R/R) Hodgkin's lymphoma (HL). However, the use of autologous stem cell transplantation (ASCT) has not been completely replaced in this setting. The use of anti-programmed death-1 (PD-1) antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoqi, Cassady, Kaniel, Zou, Zhongmin, Zhang, Xi, Feng, Yimei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293276/
https://www.ncbi.nlm.nih.gov/pubmed/34307420
http://dx.doi.org/10.3389/fmed.2021.693023
_version_ 1783725000902049792
author Wang, Xiaoqi
Cassady, Kaniel
Zou, Zhongmin
Zhang, Xi
Feng, Yimei
author_facet Wang, Xiaoqi
Cassady, Kaniel
Zou, Zhongmin
Zhang, Xi
Feng, Yimei
author_sort Wang, Xiaoqi
collection PubMed
description The emergence of new drugs has provided additional options in the treatment of relapsed and refractory (R/R) Hodgkin's lymphoma (HL). However, the use of autologous stem cell transplantation (ASCT) has not been completely replaced in this setting. The use of anti-programmed death-1 (PD-1) antibody bridging to ASCT and as maintenance after transplantation is a novel approach in HL treatment. In this case, we report that PD-1 monoclonal antibody (mAb) plus ASCT with modified BEAM regimen (carmustine + etoposide + cytarabine + melphalan) containing high-dose cytarabine to treat R/R HL may represent a promising regimen in this difficult-to-treat setting.
format Online
Article
Text
id pubmed-8293276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82932762021-07-22 Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma Wang, Xiaoqi Cassady, Kaniel Zou, Zhongmin Zhang, Xi Feng, Yimei Front Med (Lausanne) Medicine The emergence of new drugs has provided additional options in the treatment of relapsed and refractory (R/R) Hodgkin's lymphoma (HL). However, the use of autologous stem cell transplantation (ASCT) has not been completely replaced in this setting. The use of anti-programmed death-1 (PD-1) antibody bridging to ASCT and as maintenance after transplantation is a novel approach in HL treatment. In this case, we report that PD-1 monoclonal antibody (mAb) plus ASCT with modified BEAM regimen (carmustine + etoposide + cytarabine + melphalan) containing high-dose cytarabine to treat R/R HL may represent a promising regimen in this difficult-to-treat setting. Frontiers Media S.A. 2021-07-07 /pmc/articles/PMC8293276/ /pubmed/34307420 http://dx.doi.org/10.3389/fmed.2021.693023 Text en Copyright © 2021 Wang, Cassady, Zou, Zhang and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wang, Xiaoqi
Cassady, Kaniel
Zou, Zhongmin
Zhang, Xi
Feng, Yimei
Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
title Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
title_full Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
title_fullStr Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
title_full_unstemmed Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
title_short Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
title_sort case report: pd-1 blockade combined autologous hematopoietic stem cell transplantation with modified beam regimen containing high-dose cytarabine to treat r/r hodgkin's lymphoma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293276/
https://www.ncbi.nlm.nih.gov/pubmed/34307420
http://dx.doi.org/10.3389/fmed.2021.693023
work_keys_str_mv AT wangxiaoqi casereportpd1blockadecombinedautologoushematopoieticstemcelltransplantationwithmodifiedbeamregimencontaininghighdosecytarabinetotreatrrhodgkinslymphoma
AT cassadykaniel casereportpd1blockadecombinedautologoushematopoieticstemcelltransplantationwithmodifiedbeamregimencontaininghighdosecytarabinetotreatrrhodgkinslymphoma
AT zouzhongmin casereportpd1blockadecombinedautologoushematopoieticstemcelltransplantationwithmodifiedbeamregimencontaininghighdosecytarabinetotreatrrhodgkinslymphoma
AT zhangxi casereportpd1blockadecombinedautologoushematopoieticstemcelltransplantationwithmodifiedbeamregimencontaininghighdosecytarabinetotreatrrhodgkinslymphoma
AT fengyimei casereportpd1blockadecombinedautologoushematopoieticstemcelltransplantationwithmodifiedbeamregimencontaininghighdosecytarabinetotreatrrhodgkinslymphoma

Ejemplares similares